md-medicaldata

Authors

 

Jelena Obradović Gajić^1,2, Ksenija Bošković^1,2, Jelena Zvekić Svorcan^1,2, Nataša Nenadov Jovanović², Mirjana Kolundžić³, Aleksandra Savić^1,2, Dajana Dedić Novaković<sup>1,4

1</sup>Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad
²Specijalna bolnica za reumatske bolesti Novi Sad
³Dom zdravlja „Novi Sad“, Novi Sad
⁴Institut za onkologiju Vojvodine, Sremska Kamenica

 

UDK: 616.71/.72-002-085
606:616.71/.72-002

The paper was received / Rad primljen: 20.04.2024

Accepted / Rad prihvaćen: 20.05.2024.

 

Correspondence to:

dr Jelena Obradović Gajić
Specijalna bolnica za reumatske bolesti Novi Sad
Futoška 68, 21000 Novi Sad, Srbija
e-mail: jelena.ob@yahoo.com

 

 

Sažetak

 

 

Uvod. Reumatoidni artritis (RA) je hronično zapaljensko autoimuno reumatsko oboljenje, a cilj njegovog lečenja je dovođenje bolesti u stanje remisije ili nisku aktivnost. Procena aktivnosti bolesti kod obolelih od RA je važna zbog praćenja toka bolesti i efekta terapije. Cilj ovog istraživanja je ispitati nivo aktivnosti bolesti kod pacijenata sa RA lečenih biološkom terapijom. Materijal i metode: Prospektivnom studijom preseka je obuhvaćeno 56 bolesnika oba pola, koji boluju od reumatoidnog artritisa i lečeni su biološkim lekom koji modifikuje tok bolesti u Specijalnoj bolnici za reumatske bolesti Novi Sad. Ispitanici su popunjavali opšti upitnik, koji je sastavljen od samog istraživača, i sadrži demografske podatke, podatke bolesti i terapiji. Za procenu aktivnosti bolesti korišćeni su sledeći indeksi: Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI) i Simple Disease Activity Index (SDAI). Statistička obrada i analiza sprovedena je u statističkom paketu SPSS verzija 24. Rezultati: Rezultati merenja nivoa aktivnosti bolesti pokazali su da su DAS28 i CDAI u statistički značajnoj vezi sa radnim statusom (p˂0,01). SDAI je u statistički značajnoj vezi sa polom ispitanika (p˂0,05) i radnim statusom (p˂0,01). Podaci o bolesti i terapiji nisu u statistički značajnoj vezi sa DAS28. Dužina trajanja terapije biološkim lekom je u statistički značajnoj vezi sa CDAI (p˂0,01) i SDAI (p˂0,05). Zaključak: Radni status pacijenata obolelih od RA koji se leče biološkom terapijom utiče na nivo aktivnosti bolesti, odnosno viša aktivnost bolesti je kod onih koji su nezaposleni i pacijenti koji se duže leče biološkom terapijom su u remisiji ili niskoj aktivnosti bolesti.

 

Ključne reči:

reumatoidni artritis, aktivnost bolesti, biološka terapija

 

 

 

Abstract

 

Introduction. As rheumatoid arthritis (RA) is a chronic inflammatory autoimmune rheumatic disease, the aim of any prescribed treatment is to achieve remission or low disease activity. Disease activity assessment in patients with RA is important for monitoring the course of the disease and determining the therapy effectiveness. The aim of this research was to examine the level of disease activity in RA patients undergoing biological therapy. Material and methods: This prospective cross-sectional study included 56 RA patients of both sexes receiving a biological drug that modifies the disease course all of whom were treated at the Special Hospital for Rheumatic Diseases in Novi Sad. The participants completed a general questionnaire developed by the researcher for the purpose of this investigation to obtain their key demographic data, as well as information about the disease and therapy. The disease activity was assessed via Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), and Simple Disease Activity Index (SDAI). Statistical processing and analyses were carried out in the statistical package SPSS version 24. Results: Statistically significant relationships between DAS28 and CDAI scores and employment status (p˂0.01), as well as SDAI scores and gender (p˂0.05) and employment status (p˂0.01) were noted. While the disease and therapy data were not statistically significantly related to DAS28 scores, a statistically significant relationship was established for the biological drug therapy duration with CDAI (p˂0.01) and SDAI (p˂0.05). Conclusion: In RA patients receiving biological therapy, being unemployed was associated with higher disease activity, while longer therapy duration was more likely to result in disease remission or low activity.

 

Key words:

rheumatoid arthritis, disease activity, biological therapy

 

 

 

 

References:

1. Obradović J, Zvekić-Svorcan J, Nikolov T, Nikolić T, Savić A, Bošković K. Komorbiditeti i stepen aktivnosti bolesti kod obolelih od reumatoidnog artritisa – postoji li povezanost? In: 23th Kongres fizikalne i rehabilitacione medicine Srbije sa međunarodnim učešćem; 2023 Sep 21-24; Zlatibor, R Srbija; 2023. p. 335-6.
2. Stojanović M, Zdravković N, Zdravković N. Dijagnoza i terapija reumatoidnog artritisa. Apollinem medicum et Aesculapium. 2018;16(2):21-4.
3. Obradović J. Kvalitet života pacijenata sa reumatoidnim artritisom lečenih biološkom terapijom [diplomski rad]. Novi Sad: Univerzitet u Novom Sadu, Medicinski fakultet Novi Sad; 2022.
4. Martinec R, Pinjatela R, Balen D. Quality of life in patients with rheumatoid arthritis – a preliminary study. Acta Clin Croat. 2019;58(1):157-66.
5. Mikov J, Zvekić-Svorcan J, Mikov I, Minaković I, Bošković K, Janković T, et al. Razlika u depresivnosti pre i tokom COVID-19 pandemije kod pacijentkinja sa reumatoidnim artritisom lečenih biološkim lekovima. Balneoclimatologia. 2022;46(1):179-89.
6. Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid arthritis: the impact of mental health on disease: a narrative review. Rheumatol Ther. 2020;7(3):457-71.
7. Lin YJ, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.
8. Obradović Gajić J, Bošković K, Zvekić Svorcan J, Igić N. Life quality of patients with rheumatoid arthritis treated with biotherapy. Med Pregl. 2023;76(5-6):129-34.
9. Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. Semin Arthritis Rheum. 2020;50(2):276-84.
10. Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328.
11. Boyadzhieva V, Stoilov N, Ivanova M, Petrova G, Stoilov R. Real world experience of disease activity in patients with rheumatoid arthritis and response to treatment with varios biologic DMARDs. Front Pharmacol. 2018;9:1303.
12. Tatić A, Cvetinović A, Krasić J, Berberski N, Bošković K, Zvekić-Svorcan J. Uticaj fizikalne terapije na bol i zamor kod pacijenata sa reumatoidnim artritisom. MD-Medical Data. 2023;15(3):85-8.
13. Cvetinović A, Tatić A, Krasić J, Berberski N, Bošković K, Zvekić-Svorcan J. Prediktori zamora kod pacijenata sa reumatoidnim artritisom. MD-Medical Data. 2023;15(3):89-94.
14. Galloway J, Capron JP, De Leonardis F, Fakhouri W, Rose A, Kouris I, et al. The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. Rheumatol Adv Pract. 2020;4(2):rkaa041.
15. Al-Jabi SW, Seleit DI, Badran A, Koni A, Zyoud SH. Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine. Health Qual Life Outcomes. 2021;19(1):241.
16. Katchamart W, Narongroeknawin P, Chanapai, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:34.
17. Abdelsalam NM, Ebaid AM, Abdelhady EI, Bolbol SA. Workplace activity limitation and quality of life: a study on rheumatoid arthritis patients. Work. 2023;74(3):1165-72.
18. Guerra MG, Vieria R, Ganhao S, Rodrigues J, Fonseca D, Videira T, et al. First steps to understand productivity loss in Portuguese patients with rheumatoid arthritis. Acta Reumatol Port. 2019;44(3):282-3.
19. Tipsing W, Sawanyawisuth K. Predictive clinical factors in rheumatoid arthritis using disease activity and functional score. Reumatologia. 2021;59(5):309-12.
20. Čubelić D, Reihl Crnogaj M, Mayer M. Effect of disease activity and functional impairment in patients with rheumatoid arthritis on satisfaction with provided rheumatology health care. Reumatizam. 2020;67(1):27-35.
21. Choi S, Lee KH. Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study. PLoS One. 2018;13(4):e0195550.
    

PDF: 03-Obradović Gajić J. et al MD-Medical Data 2024;16(2) 093-097.pdf